ARWR Earnings & Financial Statements
Arrowhead Pharmaceuticals, Inc.
$58.37
+$0.24(+0.41%)
33
Overall
40
Value
18
Tech
42
Quality
Market Cap
$8.25B
Volume
4.16M
52W Range
$34.61 - $95.49
Target Price
$107.23
ARWR earnings and financial statements: Arrowhead Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ARWR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $829.45M | $3.55M | $240.74M | $243.23M | $138.29M |
| Operating income | $98.35M | -$601.08M | -$205.00M | -$178.51M | -$149.04M |
| EBITDA | $164.82M | -$561.51M | -$175.67M | -$162.29M | -$132.58M |
| Net income | -$1.63M | -$599.49M | -$205.28M | -$176.06M | -$140.85M |
| EPS (diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.39B | $1.14B | $765.55M | $691.94M | $710.15M |
| Total liabilities | $881.88M | $607.38M | $210.06M | $273.60M | $301.33M |
| Shareholders’ equity | $466.05M | $185.44M | $271.34M | $398.52M | $408.82M |
| Cash and equivalents | - | - | - | - | $184.40M |
| Long-term debt | $319.00M | $504.21M | $104.61M | $78.80M | $23.30M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $179.55M | -$462.85M | -$153.89M | -$136.13M | $171.31M |
| Capital expenditure | -$22.67M | -$141.47M | -$176.74M | -$52.78M | -$23.57M |
| Free cash flow | $156.85M | -$604.32M | -$330.63M | -$188.91M | $147.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARWR | $58.37 | +0.4% | 4.16M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arrowhead Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW